Primary Focus Targeted Protein Degradation

Our aspiration is to deliver disruptive clinical benefit for selected cancer patients by inhibiting pathologic genomic signaling. We will achieve our goal by eliminating critical cancer drivers and providing solution for acquired resistance as well.

Many critical cancer drivers were thought to be “undruggable.” Growing scientific knowledge, and evolution of technology, like PROTAC, shallow pocket and RNA binders enable us to access, eliminate, or reprogram these driver mutations. Increasing number of newly discovered cancer targets expand the potentially addressable cancer types as well. Astellas has established deep R&D and commercial expertise in developing and commercializing targeted medicines to selected patients (erlotinib and gilteritinib).

We are highly focused on building a novel pipeline of targeted medicines as monotherapy, and as combination partners for immune oncology medicines.
 

Assets, capabilities, and talents, which Astellas wishes to receive from its partners

[Assets and capabilities]

We are building targeted, biology specific drugs, which can potentially deliver meaningful impact on cancer. We originate our research from deep knowledge of cancer biology and expertise in target discovery, small molecule chemistry, clinical development and commercialization. We are looking to further expand and maximize our capabilities and pipeline through additional partnerships and acquisitions – sourced via our highly-active and well-coordinated external innovation, venture and business development teams, strategically located in Cambridge, Massachusetts, the Bay Area, and in Tokyo, where biotech and life science innovation is booming. 

[Talents]

We are extending our talented teams continuously. If you are interested in working in progressive, innovative teams, in an entrepreneurial diverse environment, please contact us.

 

Peter Sandor, M.D., MBA

Message from Primary Focus Lead

Peter Sandor, M.D., MBA
Senior Vice President

I believe that cancer can and will be defeated. Success requires determination, partnership and collaboration between the best minds in cancer research and development. We are building teams and a collaboration network, which is determined to make a difference for cancer patients to provide novel, innovative medicines and potentially cure cancer. We have made a strong commitment to Oncology. We believe that our competitive strategy will be successful in developing novel approaches and a strong pipeline, which will help to address unmet patient needs. We continue to expand our network and contribute to partnerships with our knowledge of science and drug development.

 

Related Research Unit